NCT04855305View on ClinicalTrials.gov

Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

November 12, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Interstitial Lung Diseases
Interventions
DRUG

Hyperpolarized 129Xe

Hyperpolarized 129Xe will be administered in multiple doses in volumes that are tailored to the participant's total lung capacity (TLC) followed by a breath hold of up to 15 seconds.

Trial Locations (4)

27710

RECRUITING

Duke University Medical Center, Durham

45219

RECRUITING

University of Cincinnati, Cincinnati

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

52242

RECRUITING

University of Iowa, Iowa City

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Children's Hospital Medical Center, Cincinnati

OTHER

collaborator

University of Cincinnati

OTHER

collaborator

University of Iowa

OTHER

lead

Bastiaan Driehuys

OTHER